What is the primary innovation of Fyodor Biotechnologies?

The primary innovation is the Urine Malaria Test (UMT). As described on Slide 1, it is the first non-blood rapid test for malaria. It is a one-step, visually read test that provides results in 25 minutes or less without the need for reagents, specialized equipment, or painful blood draws.

What evidence of market traction does the deck provide?

Slide 4 provides the most compelling traction data: the company successfully completed a market beta-test in Nigeria where 72,000 UMT units were sold through pharmacies. This demonstrates both consumer demand and the viability of their retail distribution strategy.

Which geographic markets is Fyodor targeting?

While Slide 2 shows a global heat map of malaria, Slide 4 and Slide 5 narrow the focus to Africa, specifically Nigeria and Liberia, where regulatory approvals have already been granted. Slide 5 also highlights the 313 million members of the African middle class as a key demographic.

Does the deck mention any competitors?

The deck does not name specific corporate competitors. However, Slide 3 references the '516M Malaria Blood Tests' currently performed, positioning traditional blood-based diagnostics as the primary incumbent technology they intend to disrupt.

Who are the key members of the leadership team?

The team is led by Eddy Agbo (Chairman/CEO), who holds a DVM and PhD with ties to Johns Hopkins and Amgen. He is supported by Anne Derrick (EVP & Head of Operations) with experience at Amgen and BioReliance, and Victoria Enwemadu (VP, Business Development) who previously worked at Merck (Slide 6).

Fyodor Biotechnologies Pitch Deck (2008): 7-Slide Seed Deck

See all 7 slides of the Fyodor Biotechnologies pitch deck — a 2008 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Fyodor Biotechnologies' pitch deck is a lean, 7-slide presentation that successfully raised $1.5 million in 2008. The company addresses a massive global health crisis—212 million malaria cases annually—with a disruptive, non-invasive Urine Malaria Test (UMT). The deck excels by moving quickly from the global problem to specific, localized traction, noting that regulatory approvals were already secured in Nigeria and Liberia. Despite its brevity, the deck provides clear market sizing ($789M by 2022) and showcases a high-pedigree team with experience at Amgen, Merck, and Johns Hopkins. While it…

Key takeaways

The company identifies a massive total addressable market with 212 million cases and 500,000 deaths annually (Slide 2).
Fyodor's Urine Malaria Test (UMT) is positioned as the first non-blood rapid test, requiring no reagents or equipment (Slide 1).
The deck highlights significant early traction with 72,000 units sold during a market beta-test in Nigerian pharmacies (Slide 4).
Regulatory hurdles are addressed early, confirming approvals in both Nigeria and Liberia (Slide 4).
Market projections estimate the malaria diagnostic market will grow to $789 million by 2022 at a 4.5% CAGR (Slide 5).
The team slide leverages heavy-hitting industry logos including Amgen, Merck, and Johns Hopkins University (Slide 6).
The product is designed for the '313M Middle Class' in Africa, suggesting a commercial rather than purely philanthropic model (Slide 5).
The deck omits a formal 'Ask' slide, failing to specify the amount of capital sought or the intended use of funds (Slide 7).

Introduction: The Power of a 7-Slide Narrative

Fyodor Biotechnologies provides a masterclass in brevity. In just seven slides, this 2008 seed deck manages to define a global health crisis, present a proprietary technological solution, prove market demand through a 72,000-unit beta test, and showcase a team capable of institutional-grade execution. While modern decks often bloat to 20+ slides, Fyodor focuses on the 'Urine Malaria Test' (UMT) as a singular, disruptive product.

Slide 1: The Hook

The cover slide immediately identifies the value proposition: 'Malaria Diagnosis in Minutes.' It features a high-quality product shot of the UMT packaging, which prominently lists the benefits: 'No blood, No reagents, No equipment.' By placing the CEO's contact information and the 'First non-blood test for malaria' tagline on the front page, Fyodor ensures the investor knows exactly what the company does within three seconds of opening the file.

Slides 2-3: The Problem and the Current State

Slide 2 quantifies the 'Massive Global Health Problem.' It cites 212 million cases per year and half-a-million deaths. The map highlights that while the problem is global, the concentration is heaviest in Africa and Southeast Asia. Slide 3 focuses on the clinical urgency, stating that 'Rapid diagnosis within 48 hours [is] critical.' It also identifies the current market standard: 516 million malaria blood tests. This sets the stage for a 'better, faster, cheaper' replacement play.

Slide 4: Traction and Regulatory De-risking

This is the strongest slide in the deck. It moves the conversation from theory to reality. It shows the UMT product physically sitting on pharmacy shelves under an 'Anti Malarials' sign. The slide lists two major milestones: regulatory approvals in Nigeria and Liberia, and a market beta-test in Nigeria resulting in 72,000 units sold. For a seed-stage medical device company, having 72k units of real-world sales data is an exceptional validator that bypasses many typical investor concerns regarding adoption.

Slide 5: Market Size and Growth

Fyodor uses data from Grand View Research to project a market size of $789 million by 2022, up from $580 million in 2015. Interestingly, the slide includes a map of Africa with the text '313M Middle Class.' This suggests that Fyodor is not just looking for government or NGO contracts but is targeting a burgeoning private consumer market capable of out-of-pocket purchases in pharmacies.

Slide 6: The Team

The team slide is a 'logo-heavy' display of credibility. CEO Eddy Agbo’s background includes Johns Hopkins and Amgen. EVP Anne Derrick brings experience from Amgen and MGI Pharma, while VP Victoria Enwemadu brings a Pharm.D and experience from Merck. This combination of high-level academic research and 'Big Pharma' operational experience suggests the company has the expertise to scale a regulated medical product.

Slide 7: The Conclusion

The deck ends on a mission statement: 'Democratizing Malaria Testing.' It provides clear contact information, including a phone number and website. However, it notably lacks a final 'Ask' or a roadmap of what the company intends to do next.

What Works in This Deck

Specific Traction: The mention of 72,000 units sold is the 'killer metric.' It proves that the product works, the price point is acceptable to the market, and the distribution channel (pharmacies) is viable. Regulatory Clarity: By stating that approvals are already granted in Nigeria and Liberia, the founders remove a massive 'if' from the investor's mind. Visual Communication: The product packaging is shown early and often, making the 'Urine Malaria Test' feel like a tangible, ready-to-scale consumer good rather than a laboratory experiment.

What Is Missing

The Ask: The deck never specifies how much money is being raised or what the milestones for the next 18 months are. While the catalogue facts state they raised $1.5 million, an investor reading this deck in isolation wouldn't know the terms or the target. Unit Economics: There is no mention of the cost to manufacture a test versus the retail price. In a high-volume diagnostic market, margins are everything. Competitive Landscape: While they mention blood tests generally, they don't address other rapid diagnostic tests (RDTs) that might be competing for the same pharmacy shelf space.

What a Founder Should Copy

The 'Problem-Solution' Speed: Fyodor gets through the problem, the solution, and the traction in the first four slides. Founders should copy this pace; don't spend ten slides on 'why malaria is bad' when the investor already knows it's a global crisis. The Pharmacy Shot: If you have a physical product, show it in the wild. The photo of the UMT on a shelf next to other medications is worth more than a dozen diagrams of how the technology works. It proves the 'last mile' of the business model has been solved.

Frequently asked questions

What is the primary innovation of Fyodor Biotechnologies?: The primary innovation is the Urine Malaria Test (UMT). As described on Slide 1, it is the first non-blood rapid test for malaria. It is a one-step, visually read test that provides results in 25 minutes or less without the need for reagents, specialized equipment, or painful blood draws.
What evidence of market traction does the deck provide?: Slide 4 provides the most compelling traction data: the company successfully completed a market beta-test in Nigeria where 72,000 UMT units were sold through pharmacies. This demonstrates both consumer demand and the viability of their retail distribution strategy.
Which geographic markets is Fyodor targeting?: While Slide 2 shows a global heat map of malaria, Slide 4 and Slide 5 narrow the focus to Africa, specifically Nigeria and Liberia, where regulatory approvals have already been granted. Slide 5 also highlights the 313 million members of the African middle class as a key demographic.
Does the deck mention any competitors?: The deck does not name specific corporate competitors. However, Slide 3 references the '516M Malaria Blood Tests' currently performed, positioning traditional blood-based diagnostics as the primary incumbent technology they intend to disrupt.
Who are the key members of the leadership team?: The team is led by Eddy Agbo (Chairman/CEO), who holds a DVM and PhD with ties to Johns Hopkins and Amgen. He is supported by Anne Derrick (EVP & Head of Operations) with experience at Amgen and BioReliance, and Victoria Enwemadu (VP, Business Development) who previously worked at Merck (Slide 6).

Cover slide of the Fyodor Biotechnologies pitch deck — Seed 2008 — Fyodor Biotechnologies pitch deck, slide 1 (2008)

Fyodor Biotechnologies pitch deck: the facts

Company: Fyodor Biotechnologies
Year: 2008
Stage: Seed
Slides: 7
Sector: Medical Device / Diagnostics
Deck type: Seed Pitch Deck
Outcome: Raised $1,500,000
Headquarters: Nigeria / USA

Fyodor Biotechnologies pitch deck PDF

The full Fyodor Biotechnologies deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Fyodor Biotechnologies pitch deck was used for

This deck is a 7‑slide seed‑stage presentation from 2008 by Fyodor Biotechnologies, a Baltimore‑based diagnostics company developing the Urine Malaria Test (UMT), described as the world’s first non‑blood malaria test. The deck focuses on a consumer‑friendly, urine‑based dipstick that can diagnose Plasmodium falciparum malaria in about 20–25 minutes, sold via pharmacies and designed for use at home without trained personnel or laboratory infrastructure. It highlights early commercial traction, including a Nigerian beta test in which 72,000 UMT units were sold through pharmacies, and regulatory approvals in at least Nigeria and Liberia. While the exact amount and terms of the seed raise are not documented in accessible external sources, the deck was evidently used to finance further clinical validation, regulatory work, and scale‑up of manufacturing and distribution for the UMT.

Business model: Biotech/diagnostics company developing and commercializing rapid point-of-care malaria diagnostic tests, primarily the Urine Malaria Test (UMT), a non-blood dipstick test using urine to detect Plasmodium falciparum parasite proteins in febrile patients.

Headquarters: Baltimore, Maryland, USA.

Round: Seed (as stated in the deck metadata for the 2008 presentation).

Year: 2008 (year attributed to this seed‑stage pitch deck in the source metadata).

Industry: Medical diagnostics / biotechnology, focused on malaria and infectious disease point-of-care testing.

Use of funds as presented: Externally available materials indicate that early funding, including grants, was used to support clinical validation, regulatory approvals (e.g., NAFDAC and CE Mark), and development of broader UMT versions, suggesting that the 2008 seed raise was similarly aimed at clinical trials, regulatory work, and manufacturing scale‑up, although specific line‑item uses in that round are not documented.

What happened after the Fyodor Biotechnologies deck

Since the 2008 seed‑stage deck, Fyodor Biotechnologies has advanced its urine‑based malaria diagnostic from concept and early beta testing to clinically validated, regulator‑approved commercial product status, supported by non‑dilutive grants and international recognition for its point‑of‑care innovation in low‑resource settings.

Development of the Urine Malaria Test (UMT), a urine‑based rapid diagnostic that uses recombinant monoclonal antibodies
Completion of pivotal multicenter clinical trials and performance evaluations of UMT, demonstrating accuracy that exceed
Regulatory marketing approval for UMT from Nigeria’s National Agency for Food and Drug Administration and Control (NAFDA
Additional regulatory progress including CE Mark and approvals or planned availability in Côte d’Ivoire, Kenya, Democrat
Execution of a pharmacy‑based beta test in Nigeria during which 72,000 UMT units were sold, indicating significant early
Receipt of non‑dilutive funding such as a $476,000 Phase II SBIR grant to develop a broader UMT capable of detecting bot

What the Fyodor Biotechnologies deck got right

Clear and externally validated product differentiation as a first non‑blood malaria test. Fyodor’s product proposition is highly differentiated: the Urine Malaria Test (UMT) is described across external sources as the first non‑blood malaria rapid test, enabling diagnosis via urine rather than finger‑prick blood samples, which simplifies use and reduces barriers to testing in low‑resource settings.
Early traction (72,000 units beta test) backed by later regulatory and market evidence. The deck’s highlight of a Nigerian pharmacy beta test with 72,000 units sold is supported by later narratives about UMT’s over‑the‑counter availability and NAFDAC approval, giving investors a concrete, externally corroborated traction data point at seed stage.
Clinical performance and WHO‑standard accuracy corroborate the deck’s medical claims. Subsequent multicenter pivotal clinical trials and performance evaluations show that UMT’s accuracy meets or exceeds WHO standards and is comparable to blood‑based rapid tests, substantiating the deck’s clinical promise and reducing perceived diagnostic risk.
Documented regulatory approvals align with the deck’s commercialization story. Regulatory milestones, including NAFDAC marketing approval in Nigeria and CE Mark plus additional country approvals or planned availability, demonstrate that the regulatory pathway envisioned at seed stage has been successfully navigated, validating the deck’s roadmap.
Non‑dilutive grant funding reinforces the credibility of the technology. Fyodor’s receipt of non‑dilutive funding such as a Phase II SBIR grant for broader UMT development evidences third‑party validation of the technology and increases confidence that the scientific and commercial foundations presented in the deck were considered credible by competitive grant reviewers.
Strong user‑experience and point‑of‑care positioning supported by later sources. External descriptions emphasize that UMT can be used at home without trained personnel, with a simple dipstick and ~20–25 minute readout, supporting the deck’s framing of a user‑friendly, point‑of‑care product with strong appeal in both clinical and consumer markets.

What could have been stronger

No externally verifiable detail on seed round size or investors. Externally available information about the 2008 seed round used with this deck does not document the size of the round, target amount, valuation, or specific investors, leaving a significant gap for anyone trying to assess capital structure and financing history from the deck alone.
Limited externally visible clinical performance data tied to the traction claims. Later sources emphasize regulatory approvals (e.g., NAFDAC in Nigeria) and rigorous multicenter clinical trials, but the deck era is only described as having approvals in Nigeria and Liberia and a 72,000‑unit beta test, without easily accessible contemporaneous clinical performance data (sensitivity/specificity) that investors would expect to see alongside such traction claims.
Traction numbers not matched with externally documented unit economics. The deck’s focus on the Nigerian beta test and pharmacy distribution is supported by later narratives, yet public materials do not clearly link that 72,000‑unit figure to detailed unit economics (pricing, margin, cost of goods), making it harder to externally validate business viability from the deck alone.
Early geographic focus without a clearly documented expansion roadmap from the seed deck perspective. While Fyodor’s later communications stress global deployment (multiple African countries, EU), the deck appears concentrated on Nigeria and early approvals; publicly available sources do not show a clear, time‑stamped roadmap from that seed stage to broad multi‑country commercial rollout, which may make the original go‑to‑market strategy harder to reconstruct.

How an investor would read this deck

What draws attention

Externally documented traction, including Nigeria NAFDAC marketing approval and clinical trials validating the UMT as a non‑blood malaria test, corroborate the deck’s claim of a real, disruptive product with significant early market engagement.
The 72,000‑unit Nigerian pharmacy beta test highlighted in the deck is consistent with later descriptions of UMT as an over‑the‑counter, consumer‑friendly test, making that early traction a key point for investors assessing product‑market fit in low‑resource settings.
Non‑dilutive funding via SBIR Phase II and other grants documented after 2008 indicates that the technology attracted competitive public funding, which investors often view as validation and leverage for R&D without additional equity dilution.
Regulatory progress (CE Mark, approvals in Nigeria and other African countries) and multicenter pivotal trials show that the product moved materially forward after the seed stage, an important signal when back‑checking the promises made in the 2008 deck.

Risks that stand out

Regulatory and clinical validation risk: although subsequent trials and approvals are documented, at the 2008 seed stage the UMT still faced uncertainty around clinical performance, regulatory pathways, and acceptance by national agencies, which could have delayed or blocked commercialization.
Market adoption risk: shifting malaria diagnosis from blood‑based tests and clinical settings to urine‑based, pharmacy‑sold tests required changes in clinician and patient behavior; even with a 72,000‑unit beta, long‑term adoption and repeat purchase behavior across geographies remained unproven at
Competitive and technology risk: while UMT is described as the first non‑blood malaria test, other rapid diagnostics and evolving technologies could compete on accuracy, cost, or integration into health systems, potentially limiting UMT’s market share despite its non‑invasive benefits.
Operational and scale‑up risk: manufacturing quality, supply chain reliability, and distribution partnerships across multiple African countries and the EU are critical for a low‑cost test; failures or delays in these areas could erode margins and trust, particularly given the product’s use by lay co

Questions this deck invites

What was the exact size, structure (equity vs. convertible) and lead investor of the 2008 seed round associated with this deck, and how did those funds specifically map to the milestones later achieved (clinical trials, NAFDAC approval, CE
What were the detailed sensitivity, specificity, and negative/positive predictive values for the initial UMT version marketed during or shortly after the Nigerian beta test, and how did those metrics compare to contemporaneous blood‑based r
How did Fyodor price the UMT in the pharmacy beta (wholesale and retail) and what were the unit economics (cost of goods, margin, distribution costs) observed during the 72,000‑unit test in Nigeria?
What regulatory, reimbursement, and distribution risks did Fyodor face in scaling from Nigeria to other African countries and the EU, and how were these addressed operationally and financially after the seed round?
How did non‑dilutive grant funding (e.g., SBIR Phase II) and partnerships interact with equity financing over time, and what does the current cap table and investor base look like relative to the original seed investors whose interests were

What founders can take from the Fyodor Biotechnologies deck

A focused, single‑product story built around a clearly differentiated innovation—in this case, a non‑blood, urine‑based malaria test—can be powerful when later external evidence (clinical trials, approvals, real‑world use) shows that the core thesis was correct.
Including concrete early traction metrics (such as 72,000 units sold in a pharmacy beta test) makes a seed‑stage deck more compelling, especially when those figures can later be cross‑checked against public narratives about the product’s market entry and regulatory approvals.
Positioning a medical device or diagnostic in terms of user experience—at‑home use, no blood draw, simple dipstick, 20–25 minute results—helps investors see both the clinical and consumer angles, which is reinforced when later sources consistently describe the product in those terms.
Non‑dilutive funding (such as SBIR grants) and documented regulatory progress can retroactively validate a seed‑stage deck’s roadmap, underscoring the importance of clearly articulating how early equity capital will unlock such milestones.
For global health diagnostics, anchoring the pitch in a specific high‑burden market (like Nigeria) with tangible regulatory and commercial steps, then expanding outward, can be an effective narrative—especially when later communications show approvals and planned availability in multiple countries a
Seed‑stage decks benefit from balancing bold claims (e.g., first non‑blood malaria test) with anticipated evidence; Fyodor’s subsequent clinical publications and performance evaluations demonstrate how later data can substantiate those early claims and strengthen long‑term credibility.

Fyodor Biotechnologies pitch deck: common questions

What does Fyodor Biotechnologies do?

Fyodor Biotechnologies develops rapid, point‑of‑care diagnostics for major global health problems, with a flagship product called the Urine Malaria Test (UMT), a non‑blood dipstick that detects Plasmodium falciparum malaria from urine in patients with fever. The company’s mission is to provide simple, innovative solutions that enable accurate malaria diagnosis without the need for trained personnel, laboratory equipment, or blood draws, particularly in low‑resource settings.

How does Fyodor’s Urine Malaria Test (UMT) work?

The UMT is a urine‑based rapid diagnostic test that uses recombinant monoclonal antibodies to detect Plasmodium falciparum parasite proteins (such as HRP2) excreted in the urine of febrile patients. It is a one‑step or simple multi‑step dipstick: urine is collected in a cup, the strip is dipped and left for about 20–25 minutes, and the presence of malaria is indicated by two lines on the strip vs. one line for a negative result.

How accurate is the Urine Malaria Test and how does it compare to blood tests?

According to later clinical evaluations and company information, the UMT’s overall diagnostic accuracy exceeds the World Health Organization’s 75% standard for rapid diagnostic tests and is reported around 84%, putting it on par with blood‑based rapid test kits. It is particularly effective in children under five, who are at highest risk from malaria, and is intended to be available over the counter in pharmacies for at‑home use.

Where is Fyodor’s UMT currently approved and available?

The UMT has been marketed and validated primarily in Nigeria, where Fyodor obtained approval from the national food and drug agency (NAFDAC) and conducted a beta test via pharmacies. Fyodor indicates plans and regulatory progress to make the UMT available in additional countries including Côte d’Ivoire, Kenya, the Democratic Republic of Congo, and in the European Union.

What is known about Fyodor Biotechnologies’ funding and investors?

Publicly accessible sources describe Fyodor receiving non‑dilutive funding such as US Small Business Innovation Research (SBIR) Phase II grants totaling around $476,000 to support development and validation of broader UMT versions for Plasmodium falciparum and P. vivax, and list the firm’s Baltimore address and regulatory achievements. However, specific equity investment rounds, investor names, and amounts for the 2008 seed round associated with this pitch deck are not documented in available press, filings, or investor communications, so these details cannot be reliably stated.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

Fyodor Biotechnologies pitch deck slides

Fyodor Biotechnologies pitch deck slide 1 of 7 — Fyodor Biotechnologies pitch deck — slide 1 of 7

Fyodor Biotechnologies pitch deck slide 2 of 7 — Fyodor Biotechnologies pitch deck — slide 2 of 7

Fyodor Biotechnologies pitch deck slide 3 of 7 — Fyodor Biotechnologies pitch deck — slide 3 of 7

Fyodor Biotechnologies pitch deck slide 4 of 7 — Fyodor Biotechnologies pitch deck — slide 4 of 7

Fyodor Biotechnologies pitch deck slide 5 of 7 — Fyodor Biotechnologies pitch deck — slide 5 of 7

Fyodor Biotechnologies pitch deck slide 6 of 7 — Fyodor Biotechnologies pitch deck — slide 6 of 7

What each slide of the Fyodor Biotechnologies pitch deck says

Slide 2

Massive Global Health Problem fpr dane. qo! Ey * High, Meéiimmm & & t Ni Low Income / : Countries 212 M Cases per Year Half-a-million Deaths FyodorBio [

Slide 3

Fever is an | Rapid diagnosis within 48 hours critical FyodorBio Malaria Blood Tests

Slide 4

The UMT fyodor@fyodorbio.com | on pharmacy shelves "ANTI MALARIALS | & Regulatory Approvals = . granted: Nigeria & ~ - | Liberia yo EE ee Wine >, Market Beta-testin =. y by 1° Mg ay Nigeria: 72K sold in "Elm REESN oo oc pharmacies FyodorBio

Slide 5

plies Diagnostic Future is bright Market Size Growth: 4.5% SNE $580M : 2015 313M Middle Class FyodorBio Source: Grand View Research |

Slide 6

| AES | Anne Derrick, MBA Eddy Agbo, DVM, PhD Victoria Enwemadu, Pharm.D EVP & Head of Operations Chairman/CEO & VP, Business Development eo |= ] Caneen MGI. FIT @aneeN xo UNIVERSITY ! @® BioReliance ID-Lelystad, | ; BV 1 FyodorBio

Slide text above is read directly from the Fyodor Biotechnologies deck PDF embedded on this page.